Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.

Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

Excitement builds for the 707 National Sailing Championship, happening at Port Edgar Yacht Club under the iconic Forth Bridges from July 31st to August 3rd!

NAMPA, Idaho — A small plane has crashed in a person's yard in Nampa, close to the Nampa Airport on N. Venice St. The three people who were on board the plane have died.

With this agreement, PFE acquired the exclusive rights to develop, manufacture, and commercialize 3SBio’s SSGJ-707, a bispecific antibody for PD-1 and VEGF.